Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U6LM
|
|||
| Former ID |
DAP000241
|
|||
| Drug Name |
Midazolam
|
|||
| Synonyms |
Dazolam; Dormicum; Midanium; Midazolamum; Midosed; Versed; Midazolam Base; Dormicum (TN); Hypnovel (TN); Midacum (TN); Midazolamum [INN-Latin]; Ro 21-3981; Versed (TN); Midazolam (JAN/INN); Midazolam [INN:BAN:JAN]; 4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate; 8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin; 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine; 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride; 8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine; 8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Irritability [ICD-11: MB24; ICD-10: R52, G89; ICD-9: 338] | Approved | [1], [2] | |
| Epilepsy [ICD-11: 8A60-8A68] | Phase 3 | [3] | ||
| Therapeutic Class |
Hypnotics and Sedatives
|
|||
| Company |
Roche Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H13ClFN3
|
|||
| Canonical SMILES |
CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F
|
|||
| InChI |
1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3
|
|||
| InChIKey |
DDLIGBOFAVUZHB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 59467-70-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9727, 7433688, 7847616, 7849648, 7979987, 8152621, 10528812, 14850779, 24724654, 29223297, 46507611, 48416279, 49689435, 49833675, 49978815, 50113067, 50371480, 53789031, 57322185, 92716937, 93166805, 103189248, 104305695, 126628994, 126644317, 126685927, 126723172, 127718929, 134337555, 135006020, 137003028, 140030431, 151981999, 160964028, 163414843, 164763056, 164814508, 175265628, 178100372, 179116788, 198991796, 210279804, 210282127, 223440338, 223675382, 224544524, 226421396, 241102041, 250117805, 252088595
|
|||
| ChEBI ID |
CHEBI:6931
|
|||
| ADReCS Drug ID | BADD_D01459 ; BADD_D01460 | |||
| SuperDrug ATC ID |
N05CD08
|
|||
| SuperDrug CAS ID |
cas=059467708
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Translocator protein (TSPO) | Target Info | Modulator | [4] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| HTLV-I infection | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3342). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075154. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.